Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Finasteride and Trenbolone Interaction: Avoid | Peptide Database

Compound Profiles Finasteride 5-Alpha Reductase Inhibitor | DHT Blocker for Hair Loss & BPH Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, an

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Finasteride

5-Alpha Reductase Inhibitor | DHT Blocker for Hair Loss & BPH

Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT).

Trenbolone

19-Nor Anabolic-Androgenic Steroid | Potent Recomposition Agent

Trenbolone binds to the androgen receptor with approximately three to five times the affinity of testosterone, making it one of the strongest known AR agonists among anabolic steroids. This exceptional binding affinity drives potent activation of AR-dependent gene transcription, resulting in dramatically enhanced nitrogen retention, protein synthesis, and satellite cell proliferation in skeletal muscle.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Finasteride with Trenbolone?

Combining Finasteride with Trenbolone is not recommended. 5-alpha reductase inhibitors must be avoided with trenbolone. Unlike testosterone, where 5-AR inhibitors reduce conversion to the more potent DHT, trenbolone is not primarily metabolized by 5-alpha reductase in a beneficial way. Trenbolone's androgenic metabolites are produced through different enzymatic pathways, and blocking 5-AR can paradoxically increase androgenic side effects in certain tissues. Finasteride and dutasteride provide no protective benefit against trenbolone-related hair loss, acne, or prostate effects and may worsen them.

Is Finasteride and Trenbolone safe together?

This combination carries significant risk. 5-alpha reductase inhibitors must be avoided with trenbolone. Unlike testosterone, where 5-AR inhibitors reduce conversion to the more potent DHT, trenbolone is not primarily metabolized by 5-alpha reductase in a beneficial way. Trenbolone's androgenic metabolites are produced through different enzymatic pathways, and blocking 5-AR can paradoxically increase androgenic side effects in certain tissues. Finasteride and dutasteride provide no protective benefit against trenbolone-related hair loss, acne, or prostate effects and may worsen them. Consult a healthcare professional before combining.

What are the interactions between Finasteride and Trenbolone?

5-alpha reductase inhibitors must be avoided with trenbolone. Unlike testosterone, where 5-AR inhibitors reduce conversion to the more potent DHT, trenbolone is not primarily metabolized by 5-alpha reductase in a beneficial way. Trenbolone's androgenic metabolites are produced through different enzymatic pathways, and blocking 5-AR can paradoxically increase androgenic side effects in certain tissues. Finasteride and dutasteride provide no protective benefit against trenbolone-related hair loss, acne, or prostate effects and may worsen them. This assessment has 95% confidence and is based on documented research data.

How should I time Finasteride and Trenbolone?

Finasteride has a half-life of 6-8 hours (DHT suppression persists ~24 hours) and Trenbolone has a half-life of ~3 days (acetate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

FDA-approved (as Renova 0.05%) for the mitigation of fine facial wrinkles caused by chronic sun exposure. Clinical trials demonstrate measurable improvement in fine lines, tactile roughness, and mottled hyperpigmentation with 24-48 weeks of use. Accelerates turnover of melanin-laden keratinocytes, reducing the appearance of sunspots, melasma, and post-inflammatory hyperpigmentation. Often combined with hydroquinone and a corticosteroid in the classic Kligman formula. Improves tactile smoothness and skin surface regularity by normalizing the keratinization process and promoting orderly epidermal differentiation. Stimulates new collagen deposition in the papillary dermis, partially reversing the collagen degradation caused by UV-induced photoaging. Measurable increases in procollagen I have been documented histologically. First-line topical retinoid for non-inflammatory acne. Normalizes follicular keratinization, preventing the formation of microcomedones that are the precursor to all acne lesions. Effective as monotherapy for mild inflammatory acne and as combination therapy with benzoyl peroxide or topical antibiotics for moderate acne. Reduces both comedonal and papulopustular lesions. Recommended as long-term maintenance to prevent acne relapse after initial clearance. Low-concentration formulations (0.025%) are well-tolerated for indefinite maintenance use.

Source: peptide-db.com ↗

What evidence supports FGL for human cognitive enhancement?

FGL research is primarily in animal models, where it enhances spatial memory, promotes hippocampal neurogenesis, and protects neurons from excitotoxicity. No human clinical trials exist yet. Evidence remains preclinical, making it a high-risk, exploratory peptide suitable only for research contexts with medical awareness of limited human safety data.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Ezetimibe is administered exclusively by the oral route as a 10 mg tablet taken once daily. It can be taken with or without food, at any time of day, though consistent timing is recommended for adherence. The drug does not require dose titration, as the 10 mg dose is the only approved strength and has been shown to provide the optimal balance of efficacy and tolerability. Ezetimibe is extensively glucuronidated in the small intestine and liver, and the active parent compound and its glucuronide metabolite undergo enterohepatic recirculation, contributing to the long effective half-life. Standard Lipid Management 10 mg/day Once daily Oral, with or without food On-Cycle Lipid Support (AAS Users) Once daily, throughout cycle and into PCT Combination with Statin 10 mg/day ezetimibe + statin of choice Once daily (ezetimibe can be taken same time as statin or separately) Oral

Source: peptide-db.com ↗
Side effects

Common Side Effects

Nausea (40-66%) Diarrhea (25-49%) Vomiting (15-41%) Slight heart rate increase (mean 2-5 bpm)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides